We understand your need to know more about COVID-19. If you are on RINVOQ (upadacitinib), please speak with your doctor regarding any questions you may have, including questions about the authorized COVID-19 vaccines.

To support you in your discussion with your doctor, further information about COVID-19 and vaccination may be found at the Centers for Disease Control site at

Has COVID-19 made paying for your medicine a challenge? AbbVie may be able to help. 1-800-2RINVOQ

Here for you now.

  • Resources and personalized support
  • Answers to insurance and pharmacy questions
  • Information about the RINVOQ Complete Savings Card
  • Further assistancecall 1-800-2RINVOQ

Savings on RINVOQ are available

If you are an eligible commercially insured patient, you may pay as little as $0 a month with the RINVOQ Complete Savings Card. No matter your financial or job status, there may be ways to lower the amount you pay for RINVOQ.

Resources designed around you

RINVOQ Complete provides a 1:1 personalized experience based on what you need, when you need it – from helping make sense of your insurance coverage to finding ways to help you save. To learn more, call 1-800-2RINVOQ

For more information about what AbbVie is doing to address the global COVID-19 crisis, please visit

Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit or call 1-800-2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit